Showing 1 - 10 of 34
Persistent link: https://www.econbiz.de/10010198694
We examine six molecules facing initial loss of US exclusivity (LOE, from patent expiration or challenges) between June 2009 and May 2013 that were among the 50 most prescribed molecules in May 2013. We examine prices per day of therapy (from the perspective of average revenue received by retail...
Persistent link: https://www.econbiz.de/10013062618
Persistent link: https://www.econbiz.de/10011812699
Persistent link: https://www.econbiz.de/10011405980
Persistent link: https://www.econbiz.de/10000922612
During the 1980s the share of prescriptions sold by retail pharmacies that was accounted for by generic products roughly doubled. The price response to generic entry of brand-name products has been a source of controversy. In this paper we estimate models of price responses to generic entry in...
Persistent link: https://www.econbiz.de/10012473564
During the 1980s the share of prescriptions sold by retail pharmacies that was accounted for by generic products roughly doubled. The price response to generic entry of brand-name products has been a source of controversy. In this paper we estimate models of price responses to generic entry in...
Persistent link: https://www.econbiz.de/10014158702
Persistent link: https://www.econbiz.de/10001340283
"The NBER Bulletin on Aging and Health provides summaries of publications like this. You can sign up to receive the NBER Bulletin on Aging and Health by email. The landmark Waxman-Hatch Act of 1984 represented a "grand compromise" legislation that sought to balance incentives for innovation by...
Persistent link: https://www.econbiz.de/10008688817
Persistent link: https://www.econbiz.de/10008701491